drugset / Trial / NCT02211833
Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
Exploratory evaluation of safety, tolerability, pharmacokinetics (PK), maximum tolerated dose (MTD), and efficacy of BI 2536 administered in combination with pemetrexed
Timeline
- Start
- 2006-10
- Primary completion
- 2009-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 2536 | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | — |